Patients undergoing treatment for GC between 1997 and 2001 were tested for CD55PAT-SC1expression. patients showed signs of increased apoptosis Glutarylcarnitine within the primary tumour and 60% showed signs of tumour cell regression. Comparison of the 10-year survival rates of the R0-resected CD55PAT-SC1-positive patients treated with the PAT-SC1 antibody with a historical collective of R0-resected CD55PAT-SC1-positive […]